Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions

B-cell malignancies can potentially be cured by CD19 chimeric antigen receptor (CAR) T-cell therapy. Although clinical response rates can be up to 93% in acute lymphoblastic leukemia, treatment-related antigen loss and lack of therapeutic persistence contribute to disease relapse. These shortcomings...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Zhenyuan, Cheng, Wesley A., Smith, D. Lynne, Huang, Brian, Zhang, Tiantian, Chang, Wen-Chung, Wang, Xiuli, Forman, Stephen J., Kwak, Larry W., Qin, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511472/
https://www.ncbi.nlm.nih.gov/pubmed/32451682
http://dx.doi.org/10.1007/s00262-020-02614-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511472/
https://www.ncbi.nlm.nih.gov/pubmed/32451682
http://dx.doi.org/10.1007/s00262-020-02614-8

Ejemplares similares